RepliCel Life Sciences (OTC:REPCF) touted data this week from its Phase 1/2 tendon repair study evaluating its type I collagen-expressing, hair follicle-derived fibroblasts as a treatment for Achilles tendinosis.
The clinical trial established a complete safety profile for RepliCel’s RCT-01 at 6 months and showed no serious adverse events related to the treatment or injection procedure.
All of the treated patients showed clinically relevant improvements in tendon composition, blood supply, physical function and pain sensation after receiving the company’s therapy.
Get the full story at our sister site, Drug Delivery Business News.
The post RepliCel touts tendon regeneration data for its fibroblast therapy appeared first on MassDevice.
